Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human collagen (JHM Group) is a bioengineered protein material comprising Recombinant Type I and Type III human collagen, designed to be structurally identical to native human collagen with a full-length triple-helical structure. Developed by JHM Biopharmaceutical (Hangzhou) Co., Ltd. (JHM Group) using synthetic biology and large-scale 20-ton fermentation and purification processes, this raw material serves as a bioactive scaffold for medical devices in regenerative medicine, tissue engineering, and medical aesthetics. It is utilized as the active ingredient in various formulated products, such as wound dressings, repair solutions, and dermal fillers, to promote tissue repair, wound healing, and anti-aging effects. While the raw material itself is regulated as a medical device component rather than a standalone pharmaceutical drug, it is applied or injected to facilitate healing and tissue augmentation in clinical and aesthetic settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human collagen (JHM Group).